1-855-EISAI-4-U (1-855-347-2448)

Monday - Friday, 9 am to 5 pm ET

Billing and Coding

Correct coding is the responsibility of the provider submitting a claim for the item or service. Here we provide general billing and coding information for BANZEL® and related services. Please check with the payor to verify coding or special billing requirements.

NDCs help providers and payors identify specific product package sizes. The BANZEL® NDCs are listed below.

BANZEL® Package Size

NDC

BANZEL® 200 mg tablets

62856-582-52

BANZEL® 400 mg tablets

62856-583-52

BANZEL® Oral Suspension

62856-584-46

Some payors require providers to report 11-digit NDCs when reporting a drug on a claim form. Converting the 10-digit NDC for BANZEL® to an 11-digit NDC requires the use of a leading zero in the product code section of the NDC (i.e., the middle section). Below is one example of how to report using the 11-digit NDC.

10-Digit NDC Example

11-Digit NDC Example with Leading Zero

AAAAA-BBB-CC

AAAAA-0BBB-CC

 

BANZEL® 10-Digit NDC

BANZEL® 11-Digit NDC with Leading Zero

62856-582-52

62856-0582-52

ICD diagnosis codes help providers and payors proceed with the benefit investigation and prior authorization process, if required.
The ICD-10 codes that may be applicable for BANZEL® use are listed below.

ICD-10 Diagnosis Code

Description

G40.811

Lennox-Gastaut syndrome, not intractable, with status epilepticus

G40.812

Lennox-Gastaut syndrome, not intractable, without status epilepticus

G40.801

Other epilepsy, not intractable, with status epilepticus

G40.802

Other epilepsy, not intractable, without status epilepticus

G40.803

Other epilepsy, intractable, with status epilepticus

G40.804

Other epilepsy, intractable, without status epilepticus

G40.901

Epilepsy, unspecified, not intractable, with status epilepticus

G40.909

Epilepsy, unspecified, not intractable, without status epilepticus

G40.911

Epilepsy, unspecified, intractable, with status epilepticus

G40.919

Epilepsy, unspecified, intractable, without status epilepticus

Do Your Patients Need Financial Assistance?

Programs run by Eisai and Assistance Foundations are available to help manage out-of-pocket costs

Adjunctive treatment of seizures associated with LGS

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

+ Expand - Collapse

Indication

  • BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Important Safety Information

Contraindication:

  • BANZEL is contraindicated in patients with Familial Short QT syndrome.

Warnings and Precautions:

  • Suicidal behavior and ideation: AEDs increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider if it may be related to the AED or illness because epilepsy itself can increase these risks.
  • Central nervous system reactions: Use of BANZEL has been associated with central nervous system–related adverse reactions, such as somnolence or fatigue, coordination abnormalities, dizziness, gait disturbances, and ataxia.
  • QT shortening: Formal cardiac ECG studies demonstrated shortening of the QT interval (mean = 20 msec, for doses ≥ 2400 mg twice daily) with BANZEL. Caution should be used when administering BANZEL with other drugs that shorten the QT interval.
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Multi-organ hypersensitivity syndrome, also known as DRESS, has been reported in association with BANZEL therapy. In clinical trials, hypersensitivity reactions occurred in children less than 12 years of age and within 4 weeks of starting BANZEL therapy. In addition, rare cases of DRESS and Stevens-Johnson syndrome have been reported in association with rufinamide therapy post marketing. If any of these reactions are suspected, BANZEL should be discontinued and alternative treatment started. All patients who develop a rash while taking BANZEL must be closely supervised.
  • Withdrawal of AEDs: As with all AEDs, BANZEL should be gradually withdrawn to minimize the risk of increased seizure frequency.

Adverse reactions:

  • In the pooled, double-blind, adjunctive therapy studies in adults and pediatric patients ages 3 and older, the most commonly observed (≥10%) adverse reactions with BANZEL vs placebo, respectively, were headache (25% vs 20%), dizziness (17% vs 10%), fatigue (15% vs 9%), somnolence (12% vs 9%), and nausea (11% vs 7%).
  • In a multicenter, parallel group, open-label study in pediatric patients (1 year to less than 4 years of age) the most commonly observed (≥10%) adverse reactions and with a higher frequency with BANZEL vs any other AED, respectively, were vomiting (24% vs 9%), somnolence (16% vs 0%), constipation (12% vs 9%), cough (12% vs 9%), bronchitis (12% vs 0%), rash (12% vs 9%), and decreased appetite (12% vs 9%).

For more information about BANZEL® please see Prescribing Information.

 

BANZEL® is available by prescription only.

BANZEL® Contact Information

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.

This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.

CORP-US0378